At different E:T ratios, CD276 CAR-T showed high killing efficiency (cytolysis > 80%) against different human cancer cell lines, including liver cancer, glioma, renal cancer, fibrosarcoma, breast cancer, ovarian cancer and colon cancer (Supplementary Fig. 1b). This evidence concerns the gene CD276 and breast carcinoma.